As of October 2023, among the 64 MSM patients coinfected with HIV-1/Hepatitis B, 33 (51.6%) patients were in active care and follow-up and on ART with a median CD4+ count of 451 cells/mm3 and a median HIV-1 viral load of <40 copies/mL, there were 10 (15.6%) deaths and 21 (32.8%) patients were lost to follow-up. The gene discussed is CD4; the disease is hepatitis B virus infection.